{"url_path":"/sec/enta/10-q/2026/item-3","section_key":"item-3","section_title":"Item 3 QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1177648/0001193125-26-220572-index.html","accession_number":"0001193125-26-220572","cik":"0001177648","ticker":"ENTA","issuer_name":"ENANTA PHARMACEUTICALS INC","edgar_url":"https://www.sec.gov/Archives/edgar/data/1177648/0001193125-26-220572-index.html","primary_entity_key":"0001177648","primary_entity_name":"ENANTA PHARMACEUTICALS INC"},"word_count":57,"has_tables":true,"body_markdown":"ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK\n\nDuring the six months ended March 31, 2026, there were no material changes to our market risk disclosures as set forth in Part II, Item 7A “Quantitative and Qualitative Disclosures About Market Risk” in our Annual Report on Form 10-K for the fiscal year ended September 30, 2025."}